tinosorb s

Small moleculeexperimental

Clinical trial activity

3 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
1

Earliest trial started Sep 1, 2012 (NCT01695356)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUltraviolet filter

    ultraviolet filter

Chemistry & pharmacology

Loading structure…

SMILES

CCCCC(CC)COc1ccc(-c2nc(-c3ccc(OC)cc3)nc(-c3ccc(OCC(CC)CCCC)cc3O)n2)c(O)c1
Mol. weight
627.83 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bemotrizinol
  • bemotrizinol
  • bemotrizinol
  • bemotrizinol
  • bemotrizinol
  • bemotrizinol
  • bis-ethylhexyloxyphenol methoxyphenyl triazine
  • bis-ethylhexyloxyphenol methoxyphenyl triazine
  • bis-ethylhexyloxyphenol methoxyphenyl triazine
  • tinosorb s
  • tinosorb s

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05277376Phase 3Mar 15, 2022DSM, Spaulding Clinical Research Inc.
NCT04355286Phase 1Jun 30, 2020DSM, Spaulding Clinical Research Inc.
NCT01695356Phase 4Sep 1, 2012Universidad Autonoma de San Luis Potosi
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
DSMFor profit2222020
Spaulding Clinical Research Inc.For profit2022020
Universidad Autonoma de San Luis PotosiAcademic/Hospital1112012
3 organizations
Page 1 / 1